ITeos Therapeutics Analyst Ratings
ITeos Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | 261.54% | HC Wainwright & Co. | $54 → $44 | Maintains | Buy |
| 03/17/2023 | 343.71% | HC Wainwright & Co. | → $54 | Reiterates | → Buy |
| 03/16/2023 | 162.94% | JP Morgan | $34 → $32 | Maintains | Overweight |
| 03/16/2023 | 171.16% | Wedbush | $45 → $33 | Maintains | Outperform |
| 05/13/2022 | 384.8% | SVB Leerink | $60 → $59 | Maintains | Outperform |
| 12/13/2021 | 343.71% | HC Wainwright & Co. | $37 → $54 | Maintains | Buy |
| 11/12/2021 | 343.71% | SVB Leerink | $55 → $54 | Maintains | Outperform |
| 08/13/2021 | 351.93% | SVB Leerink | $56 → $55 | Maintains | Outperform |
| 05/19/2021 | 269.76% | SVB Leerink | $60 → $45 | Maintains | Outperform |
| 05/05/2021 | 204.03% | HC Wainwright & Co. | → $37 | Initiates Coverage On | → Buy |
| 04/06/2021 | 393.02% | SVB Leerink | $37 → $60 | Maintains | Outperform |
| 11/19/2020 | 204.03% | SVB Leerink | $36 → $37 | Maintains | Outperform |
| 10/08/2020 | 269.76% | Baird | → $45 | Initiates Coverage On | → Outperform |
| 08/18/2020 | 228.68% | JP Morgan | → $40 | Initiates Coverage On | → Overweight |
| 08/18/2020 | 269.76% | Wedbush | → $45 | Initiates Coverage On | → Outperform |
| 08/18/2020 | 195.81% | SVB Leerink | → $36 | Initiates Coverage On | → Outperform |
| 08/18/2020 | 310.85% | Piper Sandler | → $50 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/09/2023 | 261.54% | HC Wainwright & Co. | 54 美元 → 44 美元 | 維護 | 購買 |
| 03/17/2023 | 343.71% | HC Wainwright & Co. | → 54 美元 | 重申 | → 購買 |
| 03/16/2023 | 162.94% | 摩根大通 | 34 美元 → 32 美元 | 維護 | 超重 |
| 03/16/2023 | 171.16% | Wedbush | 45 美元 → 33 美元 | 維護 | 跑贏大盤 |
| 05/13/2022 | 384.8% | SVB Leerink | 60 美元 → 59 美元 | 維護 | 跑贏大盤 |
| 2021 年 12 月 13 日 | 343.71% | HC Wainwright & Co. | 37 美元 → 54 美元 | 維護 | 購買 |
| 11/12/2021 | 343.71% | SVB Leerink | 55 美元 → 54 美元 | 維護 | 跑贏大盤 |
| 08/13/2021 | 351.93% | SVB Leerink | 56 美元 → 55 美元 | 維護 | 跑贏大盤 |
| 2021 年 5 月 19 日 | 269.76% | SVB Leerink | 60 美元 → 45 美元 | 維護 | 跑贏大盤 |
| 2021 年 5 月 5 日 | 204.03% | HC Wainwright & Co. | → 37 美元 | 啓動覆蓋開啓 | → 購買 |
| 04/06/2021 | 393.02% | SVB Leerink | 37 美元 → 60 美元 | 維護 | 跑贏大盤 |
| 2020 年 11 月 19 日 | 204.03% | SVB Leerink | 36 美元 → 37 美元 | 維護 | 跑贏大盤 |
| 2020 年 8 月 10 日 | 269.76% | 貝爾德 | → 45 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 08/18/2020 | 228.68% | 摩根大通 | → 40 美元 | 啓動覆蓋開啓 | → 超重 |
| 08/18/2020 | 269.76% | Wedbush | → 45 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 08/18/2020 | 195.81% | SVB Leerink | → 36 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 08/18/2020 | 310.85% | 派珀·桑德勒 | → 50 美元 | 啓動覆蓋開啓 | → 超重 |
What is the target price for ITeos Therapeutics (ITOS)?
iTEOS Therapeutics（ITOS）的目標價格是多少？
The latest price target for ITeos Therapeutics (NASDAQ: ITOS) was reported by HC Wainwright & Co. on August 9, 2023. The analyst firm set a price target for $44.00 expecting ITOS to rise to within 12 months (a possible 261.54% upside). 4 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年8月9日公佈了iTeOS Therapeutics（納斯達克股票代碼：ITOS）的最新目標股價。該分析公司將目標股價定爲44.00美元，預計ITOS將在12個月內上漲至261.54％（可能上漲261.54％）。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for ITeos Therapeutics (ITOS)?
iTEOS Therapeutics（ITOS）的最新分析師評級是多少？
The latest analyst rating for ITeos Therapeutics (NASDAQ: ITOS) was provided by HC Wainwright & Co., and ITeos Therapeutics maintained their buy rating.
iTeOS Therapeutics（納斯達克股票代碼：ITOS）的最新分析師評級由HC Wainwright & Co. 提供，iTeOS Therapeutics維持買入評級。
When is the next analyst rating going to be posted or updated for ITeos Therapeutics (ITOS)?
iTEOS Therapeutics（ITOS）的下一次分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ITeos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ITeos Therapeutics was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與iTeos Therapeutics的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。iTeOS Therapeutics的最後一次評級是在2023年8月9日提交的，因此你應該預計下一個評級將在2024年8月9日左右公佈。
Is the Analyst Rating ITeos Therapeutics (ITOS) correct?
分析師對iTEOS Therapeutics（ITOS）的評級是否正確？
While ratings are subjective and will change, the latest ITeos Therapeutics (ITOS) rating was a maintained with a price target of $54.00 to $44.00. The current price ITeos Therapeutics (ITOS) is trading at is $12.17, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的iTEOS Therapeutics（ITOS）評級保持不變，目標股價爲54.00美元至44.00美元。iTEOS Therapeutics（ITOS）目前的交易價格爲12.17美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。